Business Model – Drug Discovery
Bioactive Laboratories is a medical research company specialising in rare-plant medicines for Drug Discovery & Natural Health. The company is structured into two divisions: Bioactive Therapeutics Pty Ltd, for Drug Discovery and Bioactive Natural Health Pty Ltd for supplements and natural medicine.
Pictured here a sample of the anti-inflammatory rich bark from the khaya senegalensis tree under a compound microscope from the Plant Characterisation Project commissioned at Southern Cross University, NSW, Australia.
The Drug Discovery business will be funded eventually from a percentage of revenue from the natural health business together with government and philanthropic grants. Funding to date has been predominantly through government and private industry grants.
The resulting IP assets, generally in the form of scientific know-how and patents, will be interned into spin-off companies to focus research with partners prior to a sell off of assets most probably pre-clinical.
The company has identified areas of research where disease burden is significant and a global unmet need exists for both human health and veterinary application.
Human Anti-microbial targets
The first spin-off company is a collaboration with the Walter and Eliza Hall Institute of Medical Research in Melbourne Australia, into a human pathogenic target. The a spin-off company has been formed.
Pictured here a graph showing a successful assay on a single compound against antibiotic resistant pathogens. This is part of the anti-microbial project commissioned at Griffith University Institute for Drug Discovery in Brisbane Australia.
Our current work with Griffith University, revolves around the isolation of compounds, continuing the work that we commenced at WEHI with a major discovery in the antimicrobial field.
Veterinary – Anti-worming targets
A project showing early promise is a veterinary anthelmintic or anti-worming project with the University of Western Australia in Perth. Gut parasite resistance has become a major concern for livestock around the world. Flow on applications are within the lucrative domestic pet market.
Pipeline – Gastrointestinal & Neurodegenerative
After some significant findings, two additional pipeline projects for human health have been identified in the gastrointestinal and neurodegenerative spaces.
There has been a significant spike in the prevalence gastrointestinal disorders globally. Allergy conditions such as gluten intolerance and coeliac disease are on the rise as are the more unknown autoimmune driven conditions such as ulcerative colitis and Crohns disease. Early testing in the laboratory has shown that a group of compounds working together are responsible for an anti-inflammatory and high antioxidant action that has the potential to calm and repair gut lining.
In the neurodegenerative space, Dementia including Alzheimer’s disease is the second leading cause of death in Australia. Laboratory studies to date show that our compounds stimulate Alzheimer’s related mediators to slow down the rate of neuronal cell death. An extremely high inhibitory score of 97% from repeated studies has been achieved.
The pipeline research area for veterinary applications is also within the gastrointestinal space. Globally livestock suffer significant condition loss leading to lower weights and premature death in transit due to gastrointestinal inflammatory conditions such as gastritis.
Investors can find out more by contacting Managing Director, Rick Ferdinands via email at email@example.com to arange a confidential discussion.
Australian NATURAL THERAPIST Journal
Australian Natural Therapists Association reviews Khapregesic®
‘The Natural Therapist’ is the journal of the peak practitioner organisation, the Australian Natural Therapists Association.
TGA approved, the lost traditional medicine plant Khaya senegalensis is profiled for its polyphenol-rich wellness characteristics:
1. High anti-inflammatory and pain-relieving factors to calm an inflamed gut,
2. High antioxidant levels to aid gut-cell repair, and
3. Prebiotics to feed ‘good’ gut-bacteria.
Clinical testing of the Khaya senegalensis formula, Khapregesic® backs up traditional medicine and scientific claims of efficacy for several modern health complaints.
The khaya used in these medicines is Australian Certified Organic and sustainably grown in Australia’s Tropical North, the most pristine agricultural region on earth. All products are 100% processed in Australia under GMP in TGA licensed facilities.
Our purity credentials are impeccable. From the certified organic khaya, Khapregesic® is free from artificial flavouring, colouring, preservatives and any animal by-products making it vegan-friendly. These khaya formulations have also minimised allergic reactions by excluding gluten, wheat, dairy, lactose, corn, cereals, eggs, nuts, and yeast.